

Synthesis and Spectral Characterization of New S-Alkylated 1,2,4-Triazoles as Potential Biological Agents

STEFANIA FELICIA BARBUCEANU¹, LAURA ILEANA SOCEA^{1*}, CONSTANTIN DRAGHICI², ELENA MIHAELA PAHONTU³, THEODORA VENERA APOSTOL¹, FLORICA BARBUCEANU⁴

¹ Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, Organic Chemistry Department, 6 Traian Vuia Str., 020956, Bucharest, Romania

² Military Medical Scientific Research Center, 24-28 Gr. Cobalcescu Str., 010195, Bucharest, Romania

³ Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, General and Inorganic Chemistry Department, 6 Traian Vuia Str., 020956, Bucharest, Romania

⁴ Institute for Diagnosis and Animal Health, 63 Dr. Staicovici Str., 050557, Bucharest, Romania

In the work we presented the behavior of 5-(4-(4-X-phenylsulfonyl)phenyl)-4-(n-propyl)-2H-1,2,4-triazole-3(4H)-thiones (X= Cl or Br) with some alkylation agents. Thus, new S-alkylated 1,2,4-triazole derivatives were synthesized by reaction of the corresponding 1,2,4-triazole-3-thione derivatives with different α -halogenated compounds (ethyl bromide, ethyl chloroacetate or phenacyl bromide), in basic medium. The structures of synthesized compounds were elucidated by spectral data (¹H-NMR, ¹³C-NMR, mass spectrometry) and elemental analysis.

Keywords: 1,2,4-triazole-3-thione, alkylation, halogenated compound, S-alkylated 1,2,4-triazole

The azoles represent an important class of five-membered heterocyclic compounds recognized for the great number of compounds with biological properties, more of them being used as active substances in composition of many drugs used successfully in clinics for treating of different diseases [1]. Among these, 1,2,4-triazoles represent a class of sustained interest due to the vast range of their biological properties. Moreover, there are known many drugs containing the 1,2,4-triazole ring used as antimycotic, antimigraine, anticancer, antiviral etc [2]. Among 1,2,4-triazoles, compounds containing the 1,2,4-triazole-thione ring deserve special attention since they are reported to possess various biological activities including antimicrobial [3,4], antioxidant [5], carbonic anhydrase inhibitors [6], anticonvulsant [7,8], antitumoral [9]. The biological effect of these compounds depend largely on the nature of the substituents grafted on the 1,2,4-triazole ring [10]. At the same time these compounds are versatile intermediates in organic synthesis as they react with electrophiles at the sulfur and nitrogen atoms. The S-alkylated 1,2,4-triazoles have also increasing importance because various derivatives possess biological activity such as: analgesic [11,12], anti-inflammatory [12-14], antibacterial, antifungal [12,15], antioxidant [16], anticancer [17-19] activity.

In view of these reports and in continuation of our studies on the heterocyclic compounds with potential biological activity [20-24], in this work we extended the research in the 1,2,4-triazoles class, by study of the alkylation reaction of some 1,2,4-triazole-3-thiones with different halogenated compounds. The structures of the alkylation products were established unequivocally by ¹H-NMR, ¹³C-NMR and IR spectrometry.

Experimental part

Melting points were determined on a Bötius apparatus and are uncorrected. The FT-IR spectra were recorded on a Vertex 70 Bruker spectrometer (using KBr pellets). The NMR spectra were recorded on a Varian Gemini 300BB spectrometer at 300 MHz for ¹H-NMR and at 75 MHz for ¹³C-NMR using CDCl₃ as solvent; the chemical shifts δ , are reported in ppm relative to


tetramethylsilane (TMS) as internal standard and coupling constants J are in Hz. The content of C, H, and N was assayed using a ECS-40-10-Costeh microdosimeter.

For recording of the mass spectra, a solution (1 μ g/mL) of compound in methanol/water (0.1% ammonia) 90/10 was infused into electrospray interface working in positive mode, with 1200 L/MS/MS triple quadrupole, using a Prostar 240 SDM chromatographic pump (Varian) to 20 μ L/min flow rate. Nebulising gas was nitrogen at 42 psi, drying gas was air at 19 psi and 200°C, capillary voltage was set up at 4500 V. Protonated molecular ions were fragmented using collision with argon.

Synthesis of compounds

The key intermediates, 5-(4-(4-X-phenylsulfonyl)phenyl)-4-(n-propyl)-2H-1,2,4-triazole-3(4H)-thiones (X= Cl or Br) known in literature [25], were synthesized by cyclization, in basic media, of the corresponding acylthiosemicarbazides. The thiosemicarbazides were obtained by treatment of the corresponding hydrazides with *n*-propylisothiocyanate. For the synthesis of the corresponding hydrazides, we started from chloro/bromo-benzene and tosyl chloride, following several stages: alkylation, oxidation, esterification and hydrazinolysis [25]. By treatment of 1,2,4-triazole-3(4H)-thiones **1a,b** with ethyl bromide, in sodium ethoxide media, the 5-(4-(4-X-phenylsulfonyl)phenyl)-3-(ethylthio)-4-propyl-4H-1,2,4-triazoles **2a,b** were obtained. Also, 2-(5-(4-(4-X-phenylsulfonyl)phenyl)-4-propyl-4H-1,2,4-triazol-3-ylthio)-1-phenylethanone **3a,b** and ethyl 2-(5-(4-(4-X-phenylsulfonyl)phenyl)-4-propyl-4H-1,2,4-triazol-3-ylthio)acetate **4a,b** were obtained by reaction of the same 1,2,4-triazole-3(4H)-thiones **1a,b** with phenacyl bromide and ethyl chloroacetate, respectively. Although both N-2 endocyclic nitrogen atom and sulfur atom from 1,2,4-triazole-3-thiones **1a,b** are accessible to attack by alkylating agents, on the basis of the spectral data it has been demonstrated that alkylation of these compounds took place at the sulfur atom and not nitrogen atom.

* email: laurasoccea@gmail.com



Scheme 1. Synthesis of compounds 2a,b-4a,b

The target 1,2,4-triazole compounds were synthesized according to the synthetic route outlined in scheme 1.

General procedure for the synthesis of *S*-alkylated 1,2,4-triazoles 2a,b – 4a,b

The 1,2,4-triazole **1** (2mmol) was added to a solution of sodium ethoxide (obtained from 46 mg of sodium and 35 mL absolute ethanol). The mixture was stirred at room temperature until a solution was obtained. Then, the ethyl bromide, phenacyl bromide or ethyl chloroacetate (2mmol) was added to the solution and the mixture was stirred at room temperature for 10 h. The resulting mixture was poured into a small amount of ice-water. The precipitate obtained was filtered off, washed with water, dried and recrystallized from ethanol.

3-(4-(4-chlorophenylsulfonyl)phenyl)-5-(ethylthio)-4-propyl-4*H*-1,2,4-triazole **2a**

m.p. 135-137 °C; yield: 76 %;

IR (KBr, n, cm⁻¹): 3094m, 3072m, 3037w, 2973m, 2935m, 2877m, 1600m, 1581m, 1470m, 1321s, 1284m, 1158vs, 769s;

¹H-NMR (CDCl₃, d ppm, *J* Hz): 0.85 (t, 3H, 7.4, CH₂CH₂CH₃); 1.46 (t, 3H, 7.4, SCH₂CH₃); 1.70 (sx, 2H, 7.4, CH₂CH₂CH₃); 3.35 (q, 2H, 7.4, SCH₂CH₃); 3.89 (t, 2H, 7.4, CH₂CH₂CH₃); 7.51 (d, 2H, 8.7, H-14, H-16); 7.78 (d, 2H, 8.5, H-7, H-11); 7.91 (d, 2H, 8.7, H-13, H-17); 8.06 (d, 2H, 8.5, H-8, H-10);

¹³C-NMR (CDCl₃, d ppm): 10.83 (CH₂CH₂CH₃), 14.87 (SCH₂CH₃), 23.25 (CH₂CH₂CH₃), 27.55 (SCH₂CH₃), 46.34 (CH₂CH₂CH₃), 128.26 (C-7, C-11), 129.23 (C-8, C-10), 129.41 (C-13, C-17), 129.78 (C-14, C-16), 132.26 (C-6), 133.72 (C-15), 140.36 (C-12), 142.60 (C-9), 152.87 (C-5 triazole ring), 153.57 (C-3 triazole ring);

Elemental analysis: Anal. Calcd for C₁₉H₂₀ClN₃O₂S₂ (421.96): C, 54.08; H, 4.78; N, 9.96. Found: C, 54.02; H, 4.83; N, 9.89%;

ESI-MS, *m/z*: 422 [M+H]⁺ (³⁵Cl), 424 [M+H]⁺ (³⁷Cl); 380 (100) [M+H-C₃H₆]⁺; 382 (100) [M+H-C₃H₆]⁺; 352 [M+H-C₃H₆-C₂H₄]⁺; 354 [M+H-C₃H₆-C₂H₄]⁺; 175 [³⁵ClC₆H₄SO₂]⁺; 177 [³⁷ClC₆H₄SO₂]⁺.

3-(4-(4-bromophenylsulfonyl)phenyl)-5-(ethylthio)-4-propyl-4*H*-1,2,4-triazole **2b**

m.p. 128-130 °C; yield: 65 %;

IR (KBr, n, cm⁻¹): 3092m, 3071w, 2972m, 2932m, 2876m, 1600m, 1573s, 1470m, 1322s, 1284m, 1158vs, 581s;

¹H-NMR (CDCl₃, d ppm, *J* Hz): 0.85 (t, 3H, 7.4, CH₂CH₂CH₃); 1.47 (t, 3H, 7.1, SCH₂CH₃); 1.67 (sx, 2H, 7.4, CH₂CH₂CH₃); 3.34 (q, 2H, 7.1, SCH₂CH₃); 3.87 (t, 2H, 7.4, CH₂CH₂CH₃); 7.68 (d, 2H, 8.7, H-14, H-16); 7.78 (d, 2H, 8.7, H-7, H-11); 7.83 (d, 2H, 8.7, H-13, H-17); 8.05 (d, 2H, 8.7, H-8, H-10);

¹³C-NMR (CDCl₃, d ppm): 11.00 (CH₂CH₂CH₃), 15.05 (SCH₂CH₃), 23.44 (CH₂CH₂CH₃), 27.67 (SCH₂CH₃), 46.44 (CH₂CH₂CH₃), 128.41 (C-7, C-11), 129.07 (C-14, C-16), 129.42 (C-8, C-10), 129.52 (C-13, C-17), 132.69 (C-6), 132.91 (C-14, C-16), 140.11 (C-12), 142.54 (C-9), 152.98 (C-5 triazole ring), 153.79 (C-3 triazole ring);

Elemental analysis: Anal. Calcd for C₁₉H₂₀BrN₃O₂S₂ (466.42): C, 48.93; H, 4.32; N, 9.01. Found: C, 48.87; H, 4.27; N, 8.94%;

ESI-MS, *m/z*: 466 [M+H]⁺ (⁷⁹Br), 468 [M+H]⁺ (⁸¹Br); 424 [M+H-C₃H₆]⁺; 426 [M+H-C₃H₆]⁺; 396 [M+H-C₃H₆]⁺; 398 [M+H-C₃H₆-C₂H₄]⁺; 322 [⁷⁹BrC₆H₄SO₂C₆H₄CN+H]⁺; 324 [⁸¹BrC₆H₄SO₂C₆H₄CN+H]⁺; 219 [⁷⁹BrC₆H₄SO₂]⁺; 221 [⁸¹BrC₆H₄SO₂]⁺; 177 [C₆H₅TriazoleSH]⁺; 155 [⁷⁹BrC₆H₄]⁺; 157 [⁸¹BrC₆H₄]⁺.

2-(5-(4-(4-chlorophenylsulfonyl)phenyl)-4-propyl-4*H*-1,2,4-triazol-3-ylthio)-1-phenylethanone **3a**

m.p. 145-147 °C; yield: 64 %;

IR (KBr, n, cm⁻¹): 3090m, 3066m, 2986m, 2970m, 2937s, 2924m, 2881m, 1705s, 1598m, 1581m, 1475m, 1315s, 1284s, 1205m, 1159vs, 769s;

¹H-NMR (CDCl₃, d ppm, *J* Hz): 0.86 (t, 3H, 7.5, CH₂CH₂CH₃); 1.73 (sx, 2H, 7.5, CH₂CH₂CH₃); 3.96 (t, 2H, 7.5, CH₂CH₂CH₃); 5.00 (s, 2H, SCH₂), 7.50 (t, 2H, 7.5, H-25, H-27); 7.62 (tt, 1H, 7.5, 1.8, H-26); 7.68 (d, 2H, 8.7, H-14, H-16); 7.77 (d, 2H, 8.3, H-7, H-11); 7.83 (d, 2H, 8.7, H-13, H-17); 8.02 (dd, 2H, 1.8, 7.5, H-24, H-28); 8.06 (d, 2H, 8.3, H-8, H-10);

¹³C-NMR (CDCl₃, d ppm): 11.02 (CH₂CH₂CH₃), 23.54 (CH₂CH₂CH₃), 41.98 (SCH₂), 46.66 (CH₂CH₂CH₃), 128.41 (C-7, C-11), 128.64 (C-24, C-28), 128.99 (C-25, C-27), 129.39 (C-8, C-10), 129.53 (C-13, C-17), 129.92 (C-14, C-16), 132.44 (C-6), 134.18

(C-26), 135.23 (C-23), 139.54 (C-15), 140.50 (C-12), 142.73 (C-9), 152.14 (C-5 triazole ring), 154.10 (C-3 triazole ring), 193.08 (C=O);

Elemental analysis: Anal. calcd for $C_{25}H_{22}ClN_3O_2S_2$ (512.04): C, 58.64; H, 4.33; N, 8.21. Found: C, 58.57; H, 4.26; N, 8.17%;

ESI-MS, m/z : 512 [M+H]⁺ (³⁵Cl), 514 [M+H]⁺ (³⁷Cl); 470 [M+H-C₂H₅]⁺; 472 [M+H-C₃H₇]⁺; 364 [M+H-C₂H₅-C₂H₅CHO]⁺; 366 [M+H-C₂H₅-C₂H₅CHO]⁺; 278 [³⁵ClC₆H₄SO₂C₂H₅CN+H]⁺; 280 [³⁷ClC₆H₄SO₂C₂H₅CN+H]⁺; 175 [³⁵ClC₆H₄SO₂]⁺; 177 [³⁷ClC₆H₄SO₂]⁺; 159 [³⁵ClC₆H₄SO]⁺; 161 [³⁷ClC₆H₄SO]⁺; 111 [³⁵ClC₆H₄]⁺; 113 [³⁷ClC₆H₄]⁺.

2-(5-(4-(4-bromophenylsulfonyl)phenyl)-4-propyl-4H-1,2,4-triazol-3-ylthio)-1-phenylethanone **3b**

m.p. 142-144 °C; yield: 78 %;

IR (KBr, ν , cm⁻¹): 3088m, 3066m, 2969m, 2936s, 2923s, 2879m, 1705s, 1598m, 1572m, 14757m, 1315s, 1283s, 1205m, 1159vs, 588m;

¹H-NMR (CDCl₃, δ ppm, J Hz): 0.88 (t, 3H, 7.4, CH₂CH₂CH₃), 1.75 (sx, 2H, 7.4, CH₂CH₂CH₃), 3.97 (t, 2H, 7.4, CH₂CH₂CH₃), 5.02 (s, 2H, SCH₂), 7.51 (t, 2H, 7.8, H-25, H-27), 7.63 (t, 1H, 7.8, H-26), 7.69 (d, 2H, 8.7, H-14, H-16), 7.77 (d, 2H, 8.6, H-7, H-11), 7.84 (d, 2H, 8.7, H-13, H-17), 8.04 (bd, 2H, 7.8, H-24, H-28), 8.05 (d, 2H, 8.6, H-8, H-10);

¹³C-NMR (CDCl₃, δ ppm): 11.03 (CH₂CH₂CH₃), 23.56 (CH₂CH₂CH₃), 42.00 (SCH₂), 46.67 (CH₂CH₂CH₃), 128.30 (C-24, C-28), 128.43 (C-7, C-11), 128.65 (C-8, C-10), 129.11 (C-15), 129.44 (C-25, C-27), 129.55 (C-13, C-17), 132.46 (C-6), 132.93 (C-14, C-16), 134.19 (C-26), 135.23 (C-23), 140.08 (C-12), 142.70 (C-9), 152.17 (C-5 triazole ring), 154.10 (C-3 triazole ring), 193.09 (C=O);

Elemental analysis: Anal. Calcd for $C_{25}H_{22}BrN_3O_2S_2$ (556.49): C, 53.96; H, 3.98; N, 7.55. Found: C, 54.07; H, 3.89; N, 7.49%;

ESI-MS, m/z : 556 [M+H]⁺ (⁷⁹Br); 558 [M+H]⁺ (⁸¹Br); 514 [M+H-C₂H₅]⁺; 516 [M+H-C₃H₇]⁺; 436 [M+H-C₂H₅-C₂H₅]⁺; 438 [M+H-C₂H₅-C₂H₅]⁺; 408 [M+H-C₂H₅-C₂H₅CO]⁺; 410 [M+H-C₂H₅-C₂H₅CO]⁺; 219 [⁷⁹BrC₆H₄SO₂]⁺; 221 [⁸¹BrC₆H₄SO₂]⁺; 155 [⁷⁹BrC₆H₄]⁺; 157 [⁸¹BrC₆H₄]⁺.

ethyl 2-(5-(4-(4-chlorophenylsulfonyl)phenyl)-4-propyl-4H-1,2,4-triazol-3-ylthio)acetate **4a**

m.p. 109-110 °C; yield: 76 %;

IR (KBr, ν , cm⁻¹): 3090m, 3070m, 2980m, 2968m, 2937m, 1740s, 1600m, 1579m, 1475m, 1458m, 1318s, 1285m, 1164vs, 768s;

¹H-NMR (CDCl₃, δ ppm, J Hz): 0.87 (t, 3H, 7.4, CH₂CH₂CH₃), 1.28 (t, 3H, 7.1, -OCH₂CH₃), 1.72 (sx, 2H, 7.4, CH₂CH₂CH₃), 3.95 (t, 2H, 7.4, CH₂CH₂CH₃), 4.15 (s, 2H, SCH₂), 4.22 (q, 2H, 7.1, -OCH₂), 7.51 (d, 2H, 8.5, H-14, H-16), 7.76 (d, 2H, 8.4, H-7, H-11), 7.90 (d, 2H, 8.5, H-13, H-17), 8.05 (d, 2H, 8.4, H-8, H-10);

¹³C-NMR (CDCl₃, δ ppm): 10.99 (CH₂CH₂CH₃), 14.19 (-OCH₂CH₃), 23.60 (CH₂CH₂CH₃), 35.37 (-SCH₂), 46.65 (CH₂CH₂CH₃), 62.28 (-OCH₂), 128.38 (C-7, C-11), 128.41 (C-8, C-10), 129.52 (C-13, C-17), 129.93 (C-14, C-16), 132.46 (C-6), 139.55 (C-15), 140.51 (C-12), 142.78 (C-9), 151.55 (C-5 triazole ring), 154.12 (C-3 triazole ring), 168.30 (C=O);

Elemental analysis: Anal. Calcd for $C_{21}H_{22}ClN_3O_3S_2$ (480.00): C, 52.55; H, 4.62; N, 8.75. Found: C, 52.43; H, 4.72; N, 8.66%;

ESI-MS, m/z : 480 [M+H]⁺ (³⁵Cl), 482 [M+H]⁺ (³⁷Cl); 392 [M+H-C₂H₅-C₂H₅-H₂O]⁺; 394 [M+H-C₂H₅-C₂H₅-H₂O]⁺; 364 [M+H-C₂H₅-C₂H₅-H₂O-CO]⁺; 366 [M+H-C₂H₅-C₂H₅-H₂O-CO]⁺; 335 [M+H-C₂H₅-C₂H₅-H₂O-CO-CH₂NH]⁺; 337 [M+H-C₂H₅-C₂H₅-H₂O-CO-CH₂NH]⁺; 278 [³⁵ClC₆H₄SO₂C₆H₄CN+H]⁺; 280

2438

[³⁷ClC₆H₄SO₂C₆H₄CN+H]⁺; 175 [³⁵ClC₆H₄SO₂]⁺; 177 [³⁷ClC₆H₄SO₂]⁺; 159 [³⁵ClC₆H₄SO]⁺; 161 [³⁷ClC₆H₄SO]⁺; 111 [³⁵ClC₆H₄]⁺; 113 [³⁷ClC₆H₄]⁺. ethyl 2-(5-(4-(4-bromophenylsulfonyl)phenyl)-4-propyl-4H-1,2,4-triazol-3-ylthio)acetate **4b**

m.p. 117-119 °C; yield: 91 %;

IR (KBr, ν , cm⁻¹): 3089m, 3068m, 2968m, 2936m, 2880m, 1740s, 1600m, 1572m, 1479m, 1457m, 1317s, 1285s, 1164vs, 585m;

¹H-NMR (CDCl₃, δ ppm, J Hz): 0.87 (t, 3H, 7.4, CH₂CH₂CH₃), 1.28 (t, 3H, 7.1, -OCH₂CH₃), 1.71 (sx, 2H, 7.4, CH₂CH₂CH₃), 3.95 (t, 2H, 7.4, CH₂CH₂CH₃), 4.15 (s, 2H, SCH₂), 4.21 (q, 2H, 7.1, -OCH₂), 7.68 (d, 2H, 8.7, H-14, H-16), 7.77 (d, 2H, 8.6, H-7, H-11), 7.83 (d, 2H, 8.7, H-13, H-17), 8.05 (d, 2H, 8.6, H-8, H-10);

¹³C-NMR (CDCl₃, δ ppm): 11.01 (CH₂CH₂CH₃), 14.20 (-OCH₂CH₃), 23.61 (CH₂CH₂CH₃), 35.37 (-SCH₂), 46.65 (CH₂CH₂CH₃), 62.29 (-OCH₂), 128.42 (C-7, C-11), 129.10 (C-15), 129.43 (C-8, C-10), 129.53 (C-13, C-17), 132.47 (C-6), 132.92 (C-14, C-16), 140.07 (C-12), 142.71 (C-9), 151.56 (C-5 triazole ring), 154.12 (C-3 triazole ring), 168.32 (C=O);

Elemental analysis: Anal. Calcd for $C_{21}H_{22}BrN_3O_3S_2$ (524.45): C, 48.09; H, 4.23; N, 8.01. Found: C, 48.22; H, 4.34; N, 7.93%;

ESI-MS, m/z : 524 [M+H]⁺ (⁷⁹Br), 526 [M+H]⁺ (⁸¹Br); 482 [M+H-C₂H₅]⁺; 484 [M+H-C₃H₇]⁺; 454 [M+H-C₂H₅-C₂H₅]⁺; 456 [M+H-C₂H₅-C₂H₅]⁺; 436 [M+H-C₂H₅-C₂H₅-H₂O]⁺; 438 [M+H-C₂H₅-C₂H₅-H₂O]⁺; 408 [⁷⁹BrC₆H₄SO₂C₆H₄TriazoleSCH₂]⁺; 410 [⁸¹BrC₆H₄SO₂C₆H₄TriazoleSCH₂]⁺; 395 [⁷⁹BrC₆H₄SO₂C₆H₄TriazoleS⁺H]⁺; 397 [⁸¹BrC₆H₄SO₂C₆H₄TriazoleS⁺H]⁺; 322 [⁷⁹BrC₆H₄SO₂C₆H₄CN+H]⁺; 324 [⁸¹BrC₆H₄SO₂C₆H₄CN+H]⁺; 219 [⁷⁹BrC₆H₄SO₂]⁺; 221 [⁸¹BrC₆H₄SO₂]⁺; 203 [⁷⁹BrC₆H₄SO]⁺; 205 [⁸¹BrC₆H₄SO]⁺; 177 [C₆H₅TriazoleSH]⁺; 155 [⁷⁹BrC₆H₄]⁺; 157 [⁸¹BrC₆H₄]⁺.

Results and discussions

The structures of the compounds synthesized were elucidated by ¹H-NMR, ¹³C-NMR, IR and mass spectrometry.

In compounds synthesized, new signals due to -CH₂CH₃, -CH₂COC₆H₅ or -CH₂COOCH₂CH₃ moieties were detected in the ¹H-NMR and ¹³C-NMR spectra.

Thus, in the ¹H-NMR spectra of compounds **2a,b** obtained by treatment of 1,2,4-triazole with ethyl bromide, two new signals appeared: a quartet signal at chemical shift $\delta \sim 3.35$ ppm corresponding to two protons from CH₂ group and a triplet signal at $\delta \sim 1.47$ ppm for three protons from CH₃ group. The ¹³C-NMR spectra of these compounds displayed the signals of the carbons from CH₂ and CH₃ group at ~ 27 and ~ 15 ppm, respectively.

Compounds **3a,b** obtained from reaction of **1a,b** with phenacyl bromide showed in the ¹H-NMR spectra three new signals corresponding to phenyl fragment and in the ¹³C-NMR spectra other four signals for the same fragment (see the ¹³C-NMR spectra). The most important signal from ¹³C-NMR spectra is that characteristic to the carbon from C=O group which resonated at ~ 193 ppm. In the IR spectra of these compounds **3a,b**, the presence of absorption band from 1705 cm⁻¹ characteristic to C=O group from phenacyl fragment is a proof that the reaction of 1,2,4-triazoles **1a,b** with phenacyl bromide took place.

The ¹H-NMR spectra of compounds **4a,b** obtained by treatment of 1,2,4-triazole-3-thiones **1a,b** with ethyl chloroacetate displayed the signals derived from ester group belonging to -OCH₂CH₃ group: the quartet signal of protons from CH₂ group at ~ 4.2 ppm with coupling constant $J = 7.1$ Hz and the triplet signal of protons from CH₃ group at 1.28 ppm ($J = 7.1$ Hz). In the ¹³C NMR

spectra of these compounds, the signals belonging to the same groups were recorded at ~ 62.29 ppm (CH_2) and ~14.20 ppm (CH_3), respectively. Also, the new signal of carbon from COO ester group appeared at ~168.30 ppm. The presence of the stretching absorption band of C=O ester group in the IR spectra of the compounds **4a,b** which appeared at 1740 cm^{-1} is another proof that the reaction of 1,2,4-triazole-3-thione **1a,b** with ethyl chloroacetate occurred.

The ^1H NMR spectra of all new compounds **3** and **4** displayed the singlet signals due to S- CH_2CO group at ~ 5.00 ppm (for **3**) and 4.15 ppm (for **4**), integrating for two protons. The same S- CH_2 carbon signal was observed in the ^{13}C -NMR spectra at ~ 42 ppm (for **3**) and ~35 ppm (for **4**), respectively.

Under basic conditions, 1,2,4-triazoles **1a,b** exist, in solution, in two tautomeric forms (I and II) [26].

Due to the thiole-thione tautomeric equilibrium, alkylation of 1,2,4-triazole compounds may occur at one of the two centers (or both) with high electron density: the nitrogen atom or sulfur atom. Elucidation of the structure of these new derivatives obtained was possible by spectral analysis. On the basis of IR and NMR data, it was demonstrated that only S-alkylated compounds were obtained.

Thus, the absence of the NH and C=S stretching vibration bands in the IR spectra of new compounds **2a,b** – **4a,b** is a proof of S-alkylation. The νNH bands of 1,2,4-triazole-3-thiones **1a,b** appeared at 3435 cm^{-1} for **1a** and 3431 for **1b** and the $\nu\text{C}=\text{S}$ band appeared at 1256 cm^{-1} (**1a**) and 1238 cm^{-1} (**1b**), respectively [25].

On the other hand, the attachment of these new moiety (CH_2CH_3 , $\text{CH}_2\text{COC}_6\text{H}_5$ and $\text{COOCH}_2\text{CH}_3$) to sulfur atom and not nitrogen was clearly evidenced from the ^{13}C -NMR spectra of compounds **2a,b** – **4a,b** which showed the C-3 signal of triazole in range 153.57-154.12 ppm, more shielded than the C-3 carbon from 1,2,4-triazole-3-thione **1a,b** (~167.6 ppm) [25], indicating the absence of C=S signal. The signal of the C-5 triazole appeared in the new compounds **2-4** at δ ~ 151.55-152.98 ppm.

As it was expected, the signals of propyl groups appeared at the corresponding chemical shifts: ~3.9 ppm as triplet signal integrated for two protons ($\text{CH}_2\text{CH}_2\text{CH}_3$), ~ 1.7 ppm as sextet signal integrated for two protons ($\text{CH}_2\text{CH}_2\text{CH}_3$), and ~ 0.9 ppm as triplet signal integrated for three protons ($\text{CH}_2\text{CH}_2\text{CH}_3$), with coupling constant $J = 7.4$ -7.5 ppm. The carbon signals from the same groups propyl appeared at ~ 46 ppm ($\text{CH}_2\text{CH}_2\text{CH}_3$), ~23 ppm ($\text{CH}_2\text{CH}_2\text{CH}_3$) and ~11 ppm ($\text{CH}_2\text{CH}_2\text{CH}_3$) [25].

Also, the protons and carbons signals from phenylsulfonylphenyl fragment appeared at the values of chemical shifts in the expected region [25].

The molecular mass spectra were the additional support for the proposed structures of the compounds, the molecular ions corresponding to the halogens isotopes ($^{35}\text{Cl}/^{37}\text{Cl}$ and $^{79}\text{Br}/^{81}\text{Br}$) being in agreement with their molecular formula.

Conclusions

In this paper we present synthesis and characterization of new S-alkylated 1,2,4-triazoles by reaction of some 1,2,4-triazole-3-thiones containing arylsulfonylphenyl and *n*-propyl moieties with ethyl bromide, phenacyl bromide or ethyl chloroacetate. The structures of these compounds were confirmed by spectral techniques (NMR, IR, MS) and elemental analysis.

References

1. EL-GARHY O.H., *Int. J. Curr. Pharm. Res.*, **7**, no. 1, 2015, p. 1

2. KÜÇÜKGÜZEL 'G., ÇIKLA-SÜZGÜN P., *Eur. J. Med. Chem.*, **97**, 2015, p. 830
3. ZOUMPOULAKIS P., CAMOUTSIS Ch., PAIRAS G., SOKOVIC M., GLAMOËLIJA J., POTAMITIS C., PITSAS A., *Bioorg. Med. Chem.*, **20**, 2012, p. 1569
4. PATTAN S., GADHAVE P., TAMBE V., DENGAL S., THAKUR D., HIREMATH S.V., SHETE R.V., DEOTARSE P., *Indian J. Chem.*, **51B**, 2012, p. 297
5. NADEEM H., MOHSIN M., AFZAAL H., RIAZ S., ZAHID A., MUHAMMAD S. A., *Advances in Microbiology*, **3**, 2013, p. 366
6. SITARAM, CELIK G., KHLOYA P., VULLO D., SUPURAN C. T., SHARMA P. K., *Bioorg. Med. Chem.*, **22**, 2014, p. 1873
7. ŁUSZCZKI J. J., PLECH T., WUJEC M., *Pharmacol. Rep.*, **64**, 2012, p. 970
8. ŁUSZCZKI J.J., PLECH T., WUJEC M., *Eur. J. Pharmacology*, **690**, 2012, p. 99
9. HASSAN, G.S., EL-MESSERY, S.M., AL-OMARY, F.A.M., AL-RASHOOD, S.T., SHABAYEK, M.I., ABULFADL, Y.S., HABIB, E.-S.E., EL-HALLOUTY, S.M., FAYAD, W., MOHAMED, K.M., EL-MENSHAWI, B.S., EL-SUBBAGH H.I., *Eur. J. Med. Chem.*, **66**, 2013, p. 135
10. SHAKER R.M., *Arkivoc*, (**ix**), 2006, p. 59
11. SAIDOV N. B., KADAMOV I. M., GEORGIYANTS V. A., TARAN A. V., *Pharm. Chem. J.*, **47**, no. 11, 2014, p. 581
12. ALAM M. M., NAZREEN S., HAIDER S., SHAFI S., YAR M. S., HAMID H., ALAM M. S., *Arch. Pharm. Chem. Life Sci.*, **345**, 2012, p. 203
13. TURAN-ZITOUNI G., KAPLANCIKLI Z.A., ÖZDEMİR A., CHEVALLET P., KANDILCI H.B., GUMUSEL B., *Arch. Pharm. Chem. Life Sci.*, **340**, 2007, p. 586
14. NAVIDPOUR L., SHAFAROODI H., ABDI K., AMINI M., GHAHREMANI M. H., DEHPOUR A. R., SHAFIEE A., *Bioorg. Med. Chem.*, **14**, 2006, p. 2507
15. BAYRAK H., DEMIRBAS A., KARAOGLU S. A., DEMIRBAS N., *Eur. J. Med. Chem.*, **44**, 2009, p. 1057
16. TUMOSIENE I., JONUDKIENE I., KANTMINIENE K., BERESNEVIEIUS Z. J., *Monatsh. Chem.*, **145**, 2014, p. 319
17. ABUO-RAHMA G.E.-D.A.A., ABDEL-AZIZ M., BESHRA E.A.M., ALI T.F.S., *Eur. J. Med. Chem.* **71**, 2014, p. 185
18. POLUCCI P., MAGNAGHI P., ANGIOLINI M., ASA D., AVANZI N., BADARI A., BERTRAND J., CASALE E., CAUTERUCCIO S., CIRLA A., COZZI L., GALVANI A., JACKSON P. K., LIU Y., MAGNUSON S., MALGESINI B., NUVOLONI S., ORRENIUS C., SIRTORI F. R., RICEPUTI L., RIZZI S., TRUCCHI B., O'BRIEN T., ISACCHI A., DONATI D., D'ALESSIO R., *J. Med. Chem.*, **56**, 2013, p. 437
19. HOU Y.-P., SUN J., PANG Z.-H., LV P.-C., LI D.-D., YAN L., ZHANG H.-J., ZHENG E. X., ZHAO J., ZHU H.-L., *Bioorg. Med. Chem.*, **19**, 2011, p. 5948
20. BARBUCEANU S.-F., ILIES D. C., SARAMET G., UIVAROSI V., DRAGHICI C., RADULESCU V., *Int. J. Mol. Sci.*, **15**, no 6, 2014, p. 10908
21. BARBUCEANU S.-F., BANCESCU G., SARAMET G., BARBUCEANU F., DRAGHICI C., RADULESCU F. S., IONESCU A., NEGRES S., *Heteroat. Chem.*, **24**, no. 4, 2013, p. 309
22. BARBUCEANU, S.F., ILIES, D. C., RADULESCU, V., SOCEA, L.I., DRAGHICI, C., SARAMET, G., *Rev. Chim.(Bucharest)*, **65**, no. 10, 2014, p. 1172
23. BARBUCEANU, S.F., SARAMET, G., BANCESCU, G., DRAGHICI, C., APOSTOL, T.V., TARAN, L., DINU PIRVU, C. E., *Rev. Chim.(Bucharest)*, **64**, no. 4, 2013, p. 355
24. BARBUCEANU S. F., ALMAJAN G. L., SARAMET I., DRAGHICI C., SOCOTEANU R., BARBUCEANU F., *J. Serb. Chem.Soc.*, **74**, no. 10, 2009, p. 1041
25. SARAMET I., ALMAJAN G.-L., BĂARBUCEANU S., DRAGHICI C., BANCUI M. D., *Rev. Roum. Chim.*, **50**, no. 1, 2005, p. 19
26. SAADEH H.A., MOSLEH I.M., AL-BAKRI A.G., MUBARAK M.S., *Monatsh. Chem.*, **141**, 2010, p. 471